DiscoverThe Readout Loud319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

Update: 2024-08-22
Share

Description

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially links GLP-1 drugs to a higher rate of suicidal thoughts.

Lastly, Adam and Elaine interrogate Allison about her deeply reported corporate profile of AI drug developer Recursion. Is all the hype real?

Comments 
loading
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

2024-11-2135:08

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

2024-11-1430:16

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

2024-11-0739:22

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

2024-10-3128:25

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

2024-10-2433:46

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

2024-10-1734:19

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

2024-10-1040:08

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

2024-10-0332:48

From Tradeoffs: Race to the Bottom

From Tradeoffs: Race to the Bottom

2024-09-2828:08

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

2024-09-2632:02

323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

2024-09-1935:21

322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

2024-09-1232:57

321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

2024-09-0535:18

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

2024-08-2937:34

From "Say More": What Happens When AI Decides Your Medical Coverage

From "Say More": What Happens When AI Decides Your Medical Coverage

2024-08-2322:42

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

2024-08-2234:07

318: Drug pricing drops & psychedelics under fire

318: Drug pricing drops & psychedelics under fire

2024-08-1521:16

317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

2024-08-0828:52

316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

2024-08-0134:15

315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

2024-07-2532:46

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

STAT